Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Enanta Pharmaceuticals logo
$7.62 -0.36 (-4.51%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$7.62 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Advanced

Key Stats

Today's Range
$7.56
▼
$8.06
50-Day Range
$7.62
▼
$13.20
52-Week Range
$7.56
▼
$17.15
Volume
457,635 shs
Average Volume
340,292 shs
Market Capitalization
$222.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Moderate Buy

Company Overview

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology.

Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

The company continues to advance a pipeline of investigational medicines, including programs targeting RSV and other viral diseases, as well as inflammatory disorders. These candidates remain subject to clinical development and regulatory review.

AI Generated. May Contain Errors.

Enanta Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ENTA MarketRank™: 
2.320527201345 of 5 stars

Enanta Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 521st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Enanta Pharmaceuticals has a consensus price target of $19.00, representing about 149.3% upside from its current price of $7.62.

  • Amount of Analyst Coverage

    Enanta Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Enanta Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($2.24) to ($2.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enanta Pharmaceuticals is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enanta Pharmaceuticals is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enanta Pharmaceuticals has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Enanta Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.20% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 7.63.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 18.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enanta Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Enanta Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Enanta Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.48% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enanta Pharmaceuticals' insider trading history.
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENTA Stock News Headlines

Equities Analysts Set Expectations for ENTA Q1 Earnings
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by Wall Street Zen
Enanta Pharmaceuticals Fiscal Q4 Loss Narrows, Revenue Falls
See More Headlines

ENTA Stock Analysis - Frequently Asked Questions

Enanta Pharmaceuticals' stock was trading at $15.77 at the beginning of the year. Since then, ENTA shares have decreased by 51.7% and is now trading at $7.62.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its earnings results on Monday, November, 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.09. The biotechnology company earned $12.87 million during the quarter, compared to the consensus estimate of $14.62 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 64.32% and a negative net margin of 108.33%.

Enanta Pharmaceuticals (ENTA) raised $60 million in an initial public offering on Thursday, March 21st 2013. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share.

Enanta Pharmaceuticals' top institutional investors include State Street Corp (1.97%), Goldman Sachs Group Inc. (1.47%), Marshall Wace LLP (0.25%) and Jump Financial LLC (0.20%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus, Kathleen S Capps and Terry Vance.
View institutional ownership trends
.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Gilead Sciences (GILD), Tesla (TSLA), Micron Technology (MU), Bristol Myers Squibb (BMY), GE Aerospace (GE), NVIDIA (NVDA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
11/16/2026
Today
11/22/2026
9th Annual Evercore ISI HealthCONx Conference
12/02/2026
Next Earnings (Estimated)
2/08/2027
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ENTA
CIK
1177648
Employees
120
Year Founded
1995

Price Target and Rating

High Price Target
$20.00
Low Price Target
$17.00
Potential Upside/Downside
+149.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$81.89 million
Net Margins
-108.33%
Pretax Margin
-108.26%
Return on Equity
-64.32%
Return on Assets
-22.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.78
Quick Ratio
3.76

Sales & Book Value

Annual Sales
$63 million
Price / Sales
3.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.75 per share
Price / Book
2.77

Miscellaneous

Outstanding Shares
29,160,000
Free Float
25,812,000
Market Cap
$222.20 million
Optionable
Optionable
Beta
0.75

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:ENTA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners